Assessing Whether to Perform a Confirmatory Randomized Clinical Trial

Mahesh Parmar(University College London), Richard H. Simon, Richard S. Ungerleider(Theradex Oncology (United States))

JNCI Journal of the National Cancer Institute

November 20, 1996

10.1093/jnci/88.22.1645

Cited by 59

Related Papers

The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma

|New England Journal of Medicine|2002|3.9k

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

|The Lancet|2015|2k

Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells

|New England Journal of Medicine|2004|1.4k

Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia

|The Journal of Experimental Medicine|2001|1.1k

Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.

|Journal of Clinical Oncology|1996|914